Lazard Asset Management LLC Supernus Pharmaceuticals, Inc. Transaction History

Lazard Asset Management LLC

$68.3 Billion
Q3 2024

A detailed history of Lazard Asset Management LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 3,002 shares of SUPN stock, worth $113,295. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,002

Previous 2,205 36.15%

Holding current value

$113,295

Previous $58,000 60.34%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$25.77 - $35.16 $20,538 - $28,022	797 Added 36.15%	3,002 $93,000
Q2 2024 Aug 14, 2024	SELL	$25.99 - $33.85 $597 - $778	-23 Reduced 1.03%	2,205 $58,000
Q1 2024 May 14, 2024	SELL	$27.11 - $35.17 $264,403 - $343,013	-9,753 Reduced 81.4%	2,228 $75,000
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $1,726 - $2,255	76 Added 0.64%	11,981 $346,000
Q3 2023 Nov 14, 2023	BUY	$27.57 - $32.91 $206,995 - $247,088	7,508 Added 170.75%	11,905 $328,000
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $131,514 - $170,295	4,397 New	4,397 $132,000
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $50,382 - $61,967	-1,750 Reduced 50.03%	1,748 $59,000
Q2 2022 Aug 09, 2022	BUY	$25.33 - $34.25 $36,981 - $50,005	1,460 Added 71.64%	3,498 $101,000
Q1 2022 May 13, 2022	BUY	$28.51 - $32.9 $399 - $460	14 Added 0.69%	2,038 $65,000
Q4 2021 Feb 09, 2022	BUY	$26.37 - $34.22 $7,225 - $9,376	274 Added 15.66%	2,024 $59,000
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $4,237 - $5,650	-180 Reduced 9.33%	1,750 $46,000
Q1 2021 May 14, 2021	BUY	$24.15 - $31.45 $46,609 - $60,698	1,930 New	1,930 $50,000
Q4 2020 Feb 11, 2021	SELL	$17.7 - $25.81 $43,559 - $63,518	-2,461 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$20.2 - $25.05 $49,712 - $61,648	2,461 New	2,461 $51,000
Q1 2020 May 14, 2020	SELL	$14.45 - $24.69 $33,003 - $56,391	-2,284 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$19.93 - $29.13 $36,292 - $53,045	1,821 Added 393.3%	2,284 $54,000
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $11,792 - $15,450	463 New	463 $12,000
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $1.44 Million - $1.9 Million	-33,650 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$37.15 - $46.9 $55,725 - $70,350	-1,500 Reduced 4.27%	33,650 $1.54 Million
Q4 2017 Feb 13, 2018	SELL	$36.4 - $42.6 $673,400 - $788,100	-18,500 Reduced 34.48%	35,150 $1.4 Million
Q3 2017 Nov 13, 2017	SELL	$36.75 - $49.65 $374,850 - $506,430	-10,200 Reduced 15.97%	53,650 $2.15 Million
Q2 2017 Aug 19, 2019	SELL	N/A	-2,200 Reduced 3.33%	63,850 $2.75 Million
Q1 2017 Aug 13, 2019	SELL	N/A	-77,250 Reduced 53.91%	66,050 $2.07 Million
Q2 2016 Jul 29, 2019	BUY	N/A	143,300	143,300 $2.92 Million

Others Institutions Holding SUPN

# of Institutions

283

Shares Held

60.8M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.02B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Account

Lazard Asset Management LLC Supernus Pharmaceuticals, Inc. Transaction History